NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

MiMedx Group, Inc. (MDXG) Stock Analysis

MiMedx Group, Inc. (MDXG) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MDXG

$4.57

+$0.14 (+3.16%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MDXG with… →

MDXG Key Statistics

As of Sep 4, 2026
Trading
Open
$4.41
Previous Close
$4.43
Day's Range
4.41–4.59
52-Week Range
3.03–7.97
Volume
625.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.42
Valuation
Market Cap
$666.13M
P/E Ratio
114.25
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
22.85
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.88
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.88
EPS (ttm)Profit attributable to each share over the last twelve months.
0.04
Financials (FY)
Revenue (FY)
$418.63M+19.99%
Net Income (FY)
$48.58M+14.52%
Profit marginThe share of revenue left as profit after all costs and taxes.
1.76%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
145.76M
1-Year Return
−35.54%
Dividend and dates
Earnings Date
October 28, 2026
Avg Volume
1.28M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MDXG Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−32.50%
2025−29.63%
2024+9.69%
2023+215.47%
2022−53.97%
2021−33.48%
2020+19.79%
2019+323.46%
2018−85.80%
2017+42.33%
2016 (partial year)+17.04%

As of September 4, 2026.

MDXG Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$418.63M$48.58M11.6%
2024$348.88M$42.42M12.2%
2023$321.48M$58.23M18.1%
2022$267.84M−$30.20M−11.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$418.63M$345.62M$63.89M$48.58M11.6%
2024$348.88M$288.81M$59.31M$42.42M12.2%
2023$321.48M$266.84M$37.12M$58.23M18.1%
2022$267.84M$219.53M−$14.73M−$30.20M−11.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MDXG Valuation vs Biotechnology Median

Median of 656 stocks
MetricMDXGBiotechnology medianvs median
P/E114.2512.579.1x the median
P/S ratio1.8815.260.1x the median
Profit margin1.76%0.00%1.8 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

MiMedx Group, Inc. (MDXG) is capitalised at $666.13M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 808.

The 52-week range on file runs from $3.03 to $7.97. The most recent close on file for MDXG is $4.57, dated September 4, 2026. That is +$0.14 (+3.16%) against the previous close. The latest close sits 50.83% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $418.63M. Against the prior fiscal year total of $348.88M, that is a change of +19.99%. The same year closed with net income of $48.58M. That is +14.52% against the prior fiscal year. Profit margin runs at 1.76%. That is 1.8 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 0.04.

Across the 4 fiscal years on file, revenue moves from $267.84M in 2022 to $418.63M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 114.25 times earnings. That is 9.1 times the Biotechnology median of 12.57. On forward earnings the ratio is 22.85. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.88. Measured against sales, the shares trade at 1.88 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −35.54%. Measured over 10 years, that is −4.63% a year compounded. Beta against the wider market is reported at 1.42. Annualized volatility over the trailing 10 years is 73.88%.

Growth & Income

The record shows no dividend for MDXG.

Across the complete calendar years on file, 2019 returned +323.46% and 2018 returned −85.80%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is −32.50% year to date.

Peer Comparison

MiMedx Group, Inc. (MDXG) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MiMedx Group, Inc. MDXG $666.13M 114.3
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. MiMedx Group, Inc. trades at a P/E of 114.3.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About MiMedx Group, Inc.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

Visit website →